Skip to content
Search

Latest Stories

Hyderabad firm comes up with India’s ‘first protein subunit vaccine’

Hyderabad firm comes up with India’s ‘first protein subunit vaccine’

AN INDIAN biotech company has rolled out the country’s “first indigenously developed protein subunit vaccine” against the coronavirus.

Biological E Ltd said it has developed the vaccine, Corbevax, in collaboration with Texas Children’s Hospital Center for Vaccine Development and Baylor College of Medicine (Baylor) of Houston.

It is a recombinant protein subunit vaccine, developed from a component of the spike protein on the virus’s surface. The Hyderabad-based company said it helps the body build the immune response against the virus.

India’s drug regulator last month approved Corbevax, which, the company claims, will be “effective both in scale and affordability”.

Biological E which has already begun manufacturing the vaccine said it expects the production to cross 100 million doses per month from February. It has promised to supply 300 million doses to the government.

The first private sector biological products company of India said it plans to deliver more than one billion additional doses globally “soon”.

The company worked to make quality vaccines and pharmaceutical products “accessible to families around the world”, according to its managing director Mahima Datla.

“We resolved to develop an affordable and effective Covid vaccine. It has now become a reality.”

Founded in 1953, Biological E also developed vaccines for tetanus, Japanese encephalitis and measles and rubella over the years.

It supplies vaccines to more than 100 countries and its therapeutic products are sold in India and the US.

The company says it has eight WHO-prequalified vaccines in its portfolio.

More For You

Anil Agarwal

Vedanta Resources, which is based in the UK and owned by Indian billionaire Anil Agarwal, has been working on reducing its debt. (Photo credit: Getty Images)

Getty Images

Anil Agarwal’s Vedanta Resources signs £438 million refinancing deal

VEDANTA LTD said on Thursday that its parent company, Vedanta Resources, has signed a loan facility agreement worth up to £438 million with international banks to refinance existing debt.

The refinancing move, where old loans are replaced by new ones, often at better terms like lower interest rates, has led ratings agencies such as S&P Global Ratings and Moody's to upgrade their outlook on the company this year.

Keep ReadingShow less
Trump-Getty

Trump said that while deals are being made with some countries, others may face tariffs.

Getty Images

Trump says major trade deal with India may be finalised soon

US PRESIDENT Donald Trump on Friday said a "very big" trade deal could be finalised with India, suggesting significant movement in the ongoing negotiations between the two countries.

“We are having some great deals. We have one coming up, maybe with India. Very big one. Where we're going to open up India," Trump said at the “Big Beautiful Bill” event at the White House.

Keep ReadingShow less
Asda suffers nearly £600m loss as debt and IT costs surge

Asda co-ownerMohsin Issa. (Photo: Asda)

Asda suffers nearly £600m loss as debt and IT costs surge

ASDA, one of Britain’s largest supermarkets, has reported a pre-tax loss of £599 million for 2024, swinging sharply from a £180 million profit the previous year.

The loss comes despite total sales rising by over £1 billion to £26.8bn, as the retailer faces mounting debt costs, falling sales, and spiralling spending on a major IT overhaul, the Telegraph reported.

Keep ReadingShow less
Mounjaro

Mounjaro, or tirzepatide, is part of a new class of weight-loss medications, with trials showing patients losing an average of 20 per cent of their body weight after 72 weeks.

Reuters

Lilly to sell Mounjaro pens in India as Wegovy enters market

ELI LILLY said on Thursday that it has received approval from India's drug regulator to launch pre-filled injector pens of its weight-loss drug, Mounjaro.

The move gives the company more options to compete with Novo Nordisk, which recently launched its weight-loss drug Wegovy in the country.

Keep ReadingShow less
Grant Thornton's Anuj Chande urges UK firms to tap booming India

Anuj Chande

Grant Thornton's Anuj Chande urges UK firms to tap booming India

INDIAN companies are well placed to support the UK’s economic growth, Eastern Eye has been told by Anuj Chande, partner and head of the South Asia Business Group at Grant Thornton.

He was speaking after the publication of Grant Thornton’s India Meets Britain Tracker 2025: The latest trends in Indian investment in the UK, which was released last week. While companies in India need little encouragement to enter the UK market, the reverse is not true.

Keep ReadingShow less